About Redx Pharma
Redx Pharma is a Healthcare company based in Liverpool (United Kingdom) founded in 2010, and was acquired by Redmile Group in May 2020. Developer of small molecule therapeutics for cancer, infection, and autoimmune disease. Redx Pharma offers products and services including Zelasudil, RXC008, and Zamaporvint. Its focus areas include Diversified Pharmaceuticals and Drugs. Its legal entity is REDX PHARMA PLC. Its competitors include Merck and Astrazeneca.
Company details
Redx Pharma was founded in 2010 and is based in Liverpool, United Kingdom. Small molecule therapeutics are developed by the company targeting cancer, infectious diseases, and autoimmune conditions within the pharmaceutical sector. Operations center on drug discovery and early-stage development, with a focus on innovative treatments. The companys online presence is maintained at redxpharma.com, supporting investor and stakeholder engagement.
- Headquarters Liverpool, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website redxpharma.com
- Social LinkedIn X Facebook
- Acquired by Redmile Group (May 2020)
- Legal Name Redx Pharma Plc
- Date of Incorporation 07 Sep, 2010
- Jurisdiction MACCLESFIELD, ENGLAND
- Latest Funding Round$17.18M (USD), Post-IPO
Oct 2023
- InvestorsPolar Capital
& 6 more
- Acquired byRedmile Group
(May 2020)
Products & Services of Redx Pharma
Redx Pharma offers a comprehensive portfolio of products and services, including Zelasudil, RXC008, and Zamaporvint.
Treats interstitial lung diseases and fibrotic indications effectively.
Targets fibrostenotic Crohn’s disease with GI-restricted action.
Focuses on Wnt-ligand driven cancers as targeted therapy.
Funding Insights of Redx Pharma
- Total Rounds 11
- Last Round Post-IPO — $17.18M
- First Round $14.17M
(Mar 2016)
- Investors Count 7
Latest 10 of 11 funding rounds of Redx Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $17.18M | Post-IPO | – | – | |
| May 2022 | $42.56M | Post-IPO | – | – | |
| Dec 2020 | $34.11M | Post-IPO | – | – | |
| Apr 2020 | Post-IPO | – | – | ||
| Feb 2020 | $33.79M | Post-IPO | – | – | |
| Nov 2019 | Grant | – | – | ||
| Jun 2019 | $3.18M | Debt – Conventional | – | – | – |
| Feb 2019 | $1.13M | Post-IPO | – | – | – |
| Mar 2017 | $2.33M | Post-IPO | – | – | |
| Feb 2017 | $15.01M | Post-IPO | – | – | – |
7 investors in total: 7 institutional.
Investors in Redx Pharma
Redx Pharma has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Polar Capital, Sofinnova Partners and Invus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Private equity investments are directed across multiple sectors. | 2001 | polarcapitalfunds.com | London, United Kingdom | |
Private equity investment firm | senecaeis.co.uk | Haydock, United Kingdom | ||
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Polar Capital is recognized as a specialist active fund manager. | polarcapital.co.uk | London, United Kingdom | ||
The BioIndustry Association is recognized as the voice of the UK’s innovative life sciences and biotech industry. | bioindustry.org | London, United Kingdom |
Investor details for Redx Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Redx Pharma
32 people are tracked at Redx Pharma (9 in leadership, 6 in board & advisors, 17 in team).
| Name | Role | Group |
|---|---|---|
Lisa Anson | CEO | Leadership |
Peter Collum | CFO | Leadership |
Craig Tilston | Head, Development Operations | Leadership |
James Mead | COO | Leadership |
Helen Timmis | VP & Senior Medical Director | Leadership |
David Marshall | Head Of Procurement & Operational Finance Lead | Leadership |
Elaine Kilgour | Head Of Translational Science | Leadership |
Helen McKeever | Head, Nonclinical Operations | Leadership |
Nicolas Guisot | VP, Drug Discovery | Leadership |
Natalie Berner | Non-Executive Director | Board & advisors |
Sarah Gordon Wild | Non-Executive Director | Board & advisors |
Bernhard Kirschbaum | Non-Executive Director | Board & advisors |
Rob Scott | Non-Executive Director | Board & advisors |
Peter Presland | Non-Executive Director | Board & advisors |
Tom Burt | Non-Executive Director | Board & advisors |
Manuela la Montagna | Senior Scientist | Team |
Michal Andrä | Scientist, Medicinal Chemistry | Team |
Cliff Jones | SVP, Chemistry, DMPK & Intellectual Property | Team |
Andrew Booth | Group Financial Controller | Team |
Kirsty Houslay | Principal Scientist | Team |
12 more people are available in the full profile.
Complete people profiles for Redx Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Redx Pharma
5 dated milestones of Redx Pharma across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Redx Pharma is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $14.2M.
- Exit Acquired by Redmile Group.
- Funding Latest funding round, Post-IPO, of $17.2M.
Competitors of Redx Pharma
Redx Pharma has 2 listed competitors in our database. They include Merck and Astrazeneca.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | 781 | Pharmaceutical products are manufactured and marketed worldwide. | ||
| astrazeneca.com | 1913 | Cambridge, United Kingdom | 83,100 | Pharmaceutical and biologics products are developed and distributed worldwide. |
Detailed competitors of Redx Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Redx Pharma
The website of Redx Pharma (redxpharma.com) receives about 5.9K visits a month and ranks #2,784,687 among all websites worldwide, #3,749 in Biotechnology and Pharmaceuticals.
- Monthly visits5.9K
▼ 10.7% vs previous month
- Unique visitors2.8K
per month
- Global rank#2,784,687
among all websites
- Category rank#3,749
Health · Biotechnology and Pharmaceuticals
- Bounce rate33%
- Pages per visit2.3
- Average visit42 sec
- DevicesDesktop 23% · Mobile 77%
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Redx Pharma
Complete news archive for Redx Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Redx Pharma
Redx Pharma was founded in 2010 and raised its 1st funding round 6 years after it was founded.
Redx Pharma is headquartered in Liverpool, United Kingdom.
Redx Pharma was founded in 2010 and is based in Liverpool, United Kingdom. Small molecule therapeutics are developed by the company targeting cancer, infectious diseases, and autoimmune conditions within the pharmaceutical sector. Operations center on drug discovery and early-stage development, with a focus on innovative treatments. The companys online presence is maintained at redxpharma.com, supporting investor and stakeholder engagement.
Redx Pharma's top competitors include Merck and Astrazeneca.
Redx Pharma offers Zelasudil, RXC008, and Zamaporvint.
Redx Pharma has 7 investors. Key investors include Polar Capital, Sofinnova Partners, Invus, Redmile Group, and Polar Capital.
Redx Pharma operates through Redx Pharma Plc.
Yes. Redx Pharma was acquired by Redmile Group in May 2020.